Cognition Therapeutics advances zervimesine toward Phase 3 in DLB, faces Nasdaq bid price notice

Cognition Therapeutics reported financial results for the third quarter ended September 30, 2026, along with a business update dated November 5, 2026. CEO Lisa Ricciardi said work conducted with the Office of Neuroscience at the FDA during 2026 culminated in the development of a trial protocol for a planned registrational study of zervimesine (CT1812) in people with dementia with Lewy bodies (DLB).¹ The company said it is now evaluating its plans for manufacturing, site selection, and patient recruitment.¹

Specifically, the company said it aligned with FDA on primary and key secondary endpoints for a Phase 3 trial of zervimesine in DLB.¹ It also said it began development of the Phase 3 protocol with insights from panels of people with DLB and caregivers,¹ indicating protocol development is ongoing rather than finalized.

Separately, Cognition is working with the Alzheimer's Clinical Trial Consortium (ACTC) toward conclusion of the Phase 2 START Study in people with MCI and early Alzheimer's disease, with top-line results from START anticipated in the second half of 2027, which will inform plans for zervimesine in Alzheimer's disease.¹

The company also disclosed it received an issued patent with natural expiration of 2045 from the USPTO covering a novel crystalline form of zervimesine,¹ and that a poster developed with ACTC was accepted for presentation at the CTAD annual meeting, highlighting efficiencies achieved in the Phase 2 START study by using a p-Tau 217 assay during screening.¹

On finances, cash, cash equivalents, and restricted cash equivalents as of September 30, 2026 were approximately $31.5 million, with total obligated grant funds remaining from the National Institute of Aging at $18.2 million.¹ The company said it estimates it has sufficient cash to fund operations and capital expenditures into the fourth quarter of 2027.¹

Separately, the filing disclosed that on November 3, 2026, the company received a deficiency letter from Nasdaq notifying it that the closing bid price for its common stock had been below the minimum $1.00 per share required for continued listing under Rule 5450(a)(1) for 30 consecutive business days.¹ Cognition has 180 calendar days, or until May 3, 2027, to regain compliance.¹